

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 April 2025 (03.04.2025)



(10) International Publication Number
WO 2025/072246 A9

- (51) **International Patent Classification:**
C12N 15/113 (2010.01) C07K 7/64 (2006.01) TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (21) **International Application Number:**
PCT/US2024/048282
- (22) **International Filing Date:**
25 September 2024 (25.09.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/585,311 26 September 2023 (26.09.2023) US
63/588,115 05 October 2023 (05.10.2023) US
63/557,125 23 February 2024 (23.02.2024) US
63/640,506 30 April 2024 (30.04.2024) US
- (71) **Applicant: ENTRADA THERAPEUTICS, INC.**
[US/US]; One Design Center Place, Suite 17-500, Boston, Massachusetts 02210 (US).
- (72) **Inventors: LI, Xiang;** One Design Center Place, Suite 17-500, Boston, Massachusetts 02210 (US). **LIAN, Wen-long;** One Design Center Place, Suite 17-500, Boston, Massachusetts 02210 (US). **QIAN, Ziqing;** One Design Center Place, Suite 17-500, Boston, Massachusetts 02210 (US). **WASHBURN, Bergen;** One Design Center Place, Suite 17-500, Boston, Massachusetts 02210 (US). **LEILI, Steven;** One Design Center Place, Suite 17-500, Boston, Massachusetts 02210 (US). **BARRETT, Jennifer;** One Design Center Place, Suite 17-500, Boston, Massachusetts 02210 (US). **KENDERES, Kevin;** One Design Center Place, Suite 17-500, Boston, Massachusetts 02210 (US).
- (74) **Agent: PROVENCE, David et al.;** 111 Washington Avenue S., Suite 700, Minneapolis, Minnesota 55401 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report (Art. 21(3))
— with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))
- (48) **Date of publication of this corrected version:**
08 May 2025 (08.05.2025)
- (15) **Information about Correction:**
see Notice of 08 May 2025 (08.05.2025)

(54) **Title:** COMPOUNDS AND METHODS FOR SKIPPING EXON 50 IN DUCHENNE MUSCULAR DYSTROPHY

(57) **Abstract:** Described herein are EEV-cargo conjugates and compositions thereof comprising (a) an endosomal escape vehicle (EEV) comprising a cyclic cell penetrating peptide (cCPP); and (b) a cargo comprising an oligonucleotide that is complementary to a target sequence of a pre-mRNA transcript of a *DMD* gene, wherein the target sequence comprises at least a portion of the 5' flanking intron of exon 50, at least a portion of exon 50, at least a portion of the 3' flanking intron of exon 50, or a combination thereof. Also described herein are methods of treating DMD using the compounds described herein.